Avammune Therapeutics

Avammune is at the forefront of developing small molecule inhibitors aimed at modulating the innate immune system to treat cancer. The company's flagship product, AVA ADR 001, is a pioneering small molecule inhibitor of ADAR1, demonstrating significant interferon response in vitro through an MDA5 dependent mechanism. This compound has shown selectivity to the p150 isoform of ADAR1, confirmed by in vitro binding studies. In preclinical models, AVA ADR 001 has exhibited a micromolar EC50 and notable anti-tumor efficacy, achieving a 45% tumor growth inhibition in the B16F10 melanoma syngeneic mouse model, outperforming Anti PD1 treatment by 1.5 times. Furthermore, when combined with Anti PD1, AVA ADR 001 demonstrated a synergistic effect, doubling the efficacy compared to Anti PD1 alone. Another promising candidate, AVA NP 695, is an orally available ENPP1 inhibitor showing potential in preclinical development and is nearing the Investigational New Drug (IND) enabling stage. Avammune's business model focuses on advancing a pipeline of best-in-class and first-in-class drugs, targeting unmet needs in cancer treatment by enhancing the body's innate immune response. The company primarily serves the oncology market, aiming to provide novel therapeutic options that improve patient outcomes.

Keywords: ADAR1, ENPP1, small molecule inhibitors, cancer treatment, innate immune system, interferon response, tumor growth inhibition, preclinical development, synergistic effect, oncology market.